BMS Opdivo/Yervoy combo gains priority review
This article was originally published in Scrip
Executive Summary
In the midst of the excitement at the annual meeting in Chicago of the American Society of Clinical Oncology (ASCO), Bristol-Myers Squibb revealed it has gained a priority review for its supplemental biologics license application (sBLA) to market a combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) as a therapy for patients with previously untreated advanced melanoma.